Roche Holding AG
RHO6
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
103,249
Stocks News & Analysis
stocks
Will undervalued ASX share show progress in results?
Investors will get to see if the new strategy and capital management framework are working.
stocks
10 best US dividend aristocrats to buy now for 2026
These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,240.30 | 61.00 | -0.66% |
| CAC 40 | 8,152.82 | 21.67 | 0.27% |
| DAX 40 | 24,894.44 | 38.64 | -0.15% |
| Dow JONES (US) | 49,003.41 | 408.99 | -0.83% |
| FTSE 100 | 10,207.80 | 58.95 | 0.58% |
| HKSE | 27,725.25 | 598.30 | 2.21% |
| NASDAQ | 23,817.10 | 215.74 | 0.91% |
| Nikkei 225 | 53,038.31 | 295.23 | -0.55% |
| NZX 50 Index | 13,412.87 | 98.01 | -0.73% |
| S&P 500 | 6,978.60 | 28.37 | 0.41% |
| S&P/ASX 200 | 8,924.00 | 50.30 | -0.56% |
| SSE Composite Index | 4,160.01 | 20.10 | 0.49% |